Jonathan Ryder, MD about 1 month ago
Congrats to my colleagues for this interesting analysis.
Looking at patients who met DOTS criteria and receive dalbavancin in our hospital, they differ from the DOTS trial
Younger, more IDU, more R-sided IE (less SSTI), and more persistent bacteremia.
Yet, outcomes similar #IDSky
add a skeleton here at some point